C12N 2310/3231
Having an additional ring
Official title: having an additional ring, e.g. LNA, ENA
C12N2310/3231 (Having an additional ring) appears on 1,031 US grants and 2,183 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,031
- Published applications
- 2,183
- Assignees
- 580
- Inventors
- 2,478
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 2 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 6 |
| 2004 | 0 | 8 |
| 2005 | 1 | 8 |
| 2006 | 0 | 11 |
| 2007 | 2 | 25 |
| 2008 | 1 | 14 |
| 2009 | 5 | 38 |
| 2010 | 14 | 37 |
| 2011 | 15 | 44 |
| 2012 | 21 | 58 |
| 2013 | 29 | 60 |
| 2014 | 40 | 91 |
| 2015 | 66 | 139 |
| 2016 | 69 | 134 |
| 2017 | 90 | 129 |
| 2018 | 91 | 130 |
| 2019 | 90 | 143 |
| 2020 | 86 | 145 |
| 2021 | 86 | 156 |
| 2022 | 84 | 180 |
| 2023 | 61 | 167 |
| 2024 | 67 | 166 |
| 2025 | 61 | 178 |
| 2026 | 50 | 114 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for delivery of antisense compounds22 Sep 2026US 12,741,989 B2Entrada Therapeutics, Inc.
- Linked target capture1 Sep 2026US 12,723,277 B2Ncan Genomics, Inc.
- Polynucleotide conjugates comprising PLN-targeting anti-transferrin receptor antibodies and method of use thereof to treat PLN-associated cardiomyopathies18 Aug 2026US 12,708,669 B2Atrium Therapeutics, Inc.
- Muscle targeting complexes and formulations for treating myotonic dystrophy4 Aug 2026US 12,697,394 B2Dyne Therapeutics, Inc.
- Modified antisense oligonucleotide for inhibition of FoxP3 expression14 Jul 2026US 12,680,098 B2Secarna Pharmaceuticals GmbH & Co. KG
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
- Methods of treatment of chronic kidney disease8 Oct 2026US 2026/0308590 A1AstraZeneca AB
- Treatment of gpam related diseases and disorders8 Oct 2026US 2026/0308594 A1Empirico Inc.
- Antisense oligomer formulations8 Oct 2026US 2026/0308595 A1Stoke Therapeutics, Inc.
- Methods of minimising effects of smoke exposure8 Oct 2026US 2026/0308597 A1Rage Biotech Pty Ltd
Most cited
By later US patents
- Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation323US 7,696,345 B2Isis Pharmaceuticals, Inc. · 2010
- Oligonucleotides with alternating segments of locked and non-locked nucleotides183US 7,687,617 B2Santaris Pharma A/S · 2010
- Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure135US 7,534,879 B2Academisch Ziekenhuis Leiden · 2009
- Oligomeric compounds and compositions for use in modulation of small non-coding RNAs132US 7,683,036 B2Regulus Therapeutics Inc. · 2010
- Targeted chromosomal genomic alterations with modified single stranded oligonucleotides126US 6,936,467 B2University of Delaware · 2005